Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | LATS1 | O95835 | 2/20 | 0.35 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2630262 | 0.94 | KIT (0.36) | KDRKITDYRK1A | |
| SCHEMBL2630263 | 0.93 | KIT (0.35) | KIT | |
| SCHEMBL2630277 | 0.90 | JAK1 (0.39) | KIT | |
| SCHEMBL2630264 | 0.89 | KIT (0.35) | KIT | |
| SCHEMBL2630432 | 0.86 | LATS1 (0.49) | KDRFLT1LATS1LATS2DYRK1A | |
| SCHEMBL2630296 | 0.82 | — | — | |
| SCHEMBL13059457 | 0.81 | JAK3 (0.40) | KDRKITDYRK1A | |
| SCHEMBL2630240 | 0.79 | JAK2 (0.44) | KDRFLT4LATS1LATS2 | |
| SCHEMBL2630429 | 0.79 | CDK9 (0.43) | KDRLATS1LATS2DYRK1A | |
| SCHEMBL2630238 | 0.79 | JAK2 (0.42) | LATS1LATS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160008359-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2016-01-14 | — | — | US | disclosed |
| US-20160008359-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2016-01-14 | — | — | US | disclosed |
| US-8822681-B2 | Azaindoles useful as inhibitors of janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822681-B2 | Azaindoles useful as inhibitors of janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130237516-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237516-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-12 | — | — | US | disclosed |
| US-8450489-B2 | Azaindoles useful as inhibitors of janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450489-B2 | Azaindoles useful as inhibitors of janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120165307-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165307-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-8163917-B2 | Azaindoles useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163917-B2 | Azaindoles useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100311743-A1 | Azaindoles Useful as Inhibitors of Janus Kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311743-A1 | Azaindoles Useful as Inhibitors of Janus Kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-7767816-B2 | for treating proliferative disorders, cardiac disorders, neurodegenerative disorders, autoimmune disorders, conditions associated with organ transplantation, inflammatory disorders, and/or immunologically mediated disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767816-B2 | for treating proliferative disorders, cardiac disorders, neurodegenerative disorders, autoimmune disorders, conditions associated with organ transplantation, inflammatory disorders, and/or immunologically mediated disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-03 | — | — | US | disclosed |
| US-20070203142-A1 | for treating proliferative disorders, cardiac disorders, neurodegenerative disorders, autoimmune disorders, conditions associated with organ transplantation, inflammatory disorders, and/or immunologically mediated disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| US-20070203142-A1 | for treating proliferative disorders, cardiac disorders, neurodegenerative disorders, autoimmune disorders, conditions associated with organ transplantation, inflammatory disorders, and/or immunologically mediated disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008359-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | JAK3, JAK1, JAK2 | KDR 1477/4885FLT1 1703/4885FLT4 1647/4885 |
| US-20070203142-A1 | for treating proliferative disorders, cardiac disorders, neurodegenerative disorders, autoimmune disorders, conditions associated with organ transplantation, inflammatory disorders, and/or immunologically mediated disorders | JAK1, JAK3, MYLK2 | KDR 3475/4885FLT1 1445/4885FLT4 1622/4885 |
| US-20120165307-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | JAK3, JAK1, JAK2 | KDR 1477/4885FLT1 1703/4885FLT4 1647/4885 |
| US-20130237516-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | JAK3, JAK1, JAK2 | KDR 1477/4885FLT1 1703/4885FLT4 1647/4885 |
| US-20100311743-A1 | Azaindoles Useful as Inhibitors of Janus Kinases | JAK3, JAK1, JAK2 | KDR 1477/4885FLT1 1703/4885FLT4 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.